Wolfe Research Initiates Coverage on Beta Bionics (NASDAQ:BBNX)

Wolfe Research initiated coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report published on Friday, MarketBeat Ratings reports. The firm issued an outperform rating and a $20.00 price target on the stock.

Other equities analysts have also issued research reports about the stock. Stifel Nicolaus started coverage on shares of Beta Bionics in a report on Monday, February 24th. They set a “buy” rating and a $25.00 price target on the stock. Leerink Partners started coverage on shares of Beta Bionics in a report on Monday, February 24th. They set an “outperform” rating and a $28.00 price target on the stock. Robert W. Baird started coverage on shares of Beta Bionics in a report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target on the stock. LADENBURG THALM/SH SH started coverage on shares of Beta Bionics in a report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target on the stock. Finally, Piper Sandler started coverage on shares of Beta Bionics in a research note on Monday, February 24th. They set an “overweight” rating and a $26.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.13.

Beta Bionics Trading Up 12.0%

Shares of NASDAQ:BBNX opened at $17.20 on Friday. The business’s fifty day simple moving average is $12.38. Beta Bionics has a 52 week low of $8.89 and a 52 week high of $24.50.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.01).

Hedge Funds Weigh In On Beta Bionics

A number of hedge funds have recently bought and sold shares of BBNX. Strs Ohio bought a new position in Beta Bionics during the first quarter worth $29,000. Corebridge Financial Inc. bought a new stake in Beta Bionics in the first quarter valued at $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Beta Bionics in the first quarter valued at $95,000. MetLife Investment Management LLC bought a new stake in Beta Bionics in the first quarter valued at $102,000. Finally, Deutsche Bank AG bought a new stake in Beta Bionics in the first quarter valued at $148,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.